NEWS RELEASE: Bio-Gate and OSSIS expand into additional international markets with HyProtect™ Coatings on Compassionate Care implants.
- Stronger and expanded international market access of OSSIS after acquisition by Zimmer Biomet
- Increased awareness of HyProtect™ coatings
- Increased volume of HyProtect™ coated implants
Introduction
Bio-Gate AG, a leading provider of innovative technologies and individual solutions for health and hygiene, is partnering with OSSIS Ltd. from New Zealand to introduce and market the innovative HyProtect™ coating technology in additional markets. This collaboration focuses on single patient compassionate care cases in human medicine with orthopedic revision implants.
Successful Partnership
Bio-Gate has been working successfully with OSSIS for several years, coating revision implants with the HyProtect™ technology. These titanium implants, manufactured by Ossis using 3D printing, are primarily used in orthopedic revisions for patients at high risk of infection. Despite OSSIS being acquired by Zimmer Biomet, the partnership with Bio-Gate will continue unchanged and will now expand to further regions worldwide through the expanded global network.
Global Impact
Bio-Gate coated titanium implants have already been used in over a hundred single-patient revision surgeries. These antimicrobial implants are mainly used in patients at risk of infection due to previous orthopedic revisions or cancer. The success of these cases has led to an increased interest among international clinics and surgeons. The high quality of the HyProtect™ coating has been proven through successful operations and positive scientific publications, leading hospitals to request Bio-Gate’s coated implants for high-risk patients.
Sustainable Development Goals (SDGs)
This partnership aligns with several SDGs, including:
- Good Health and Well-being: By reducing the risk of infection in high-risk patients, the HyProtect™ coating contributes to improving health outcomes and well-being.
- Industry, Innovation, and Infrastructure: The innovative HyProtect™ coating technology represents a significant advancement in the medical industry, enhancing the quality and effectiveness of orthopedic revision implants.
- Partnerships for the Goals: The collaboration between Bio-Gate and OSSIS demonstrates the importance of partnerships in achieving sustainable development objectives.
Future Growth
The expanded network and increased volume of implants manufactured using 3D printing are expected to drive the growth of Bio-Gate’s medical technology business. This growth will enable Bio-Gate to further develop and promote the HyProtect™ coating, reducing the risk of re-infection in patients at high risk.
About Bio-Gate AG
Bio-Gate AG is a medical technology company that develops and markets applications using silver technology to prevent infections and improve health. Their specialty lies in using pure silver to treat materials and surfaces, providing long-term protection against bacteria and pathogens. Bio-Gate AG offers a range of products that provide antimicrobial protection, including material enhancement, surface coating, and testing services. With a focus on the entire value-adding chain, from development to production, Bio-Gate AG is committed to delivering innovative solutions for infection prevention.
Note: The opinions expressed in this news release are the author’s own and do not necessarily reflect those of Medical Design & Outsourcing or its employees.
SDGs, Targets, and Indicators
| SDGs | Targets | Indicators |
|---|---|---|
| SDG 3: Good Health and Well-being | Target 3.8: Achieve universal health coverage, including financial risk protection, access to quality essential healthcare services, and access to safe, effective, quality, and affordable essential medicines and vaccines for all | Indicator: Increased volume of HyProtect™ coated implants used in orthopedic revisions for patients at risk of infection |
| SDG 9: Industry, Innovation, and Infrastructure | Target 9.5: Enhance scientific research, upgrade the technological capabilities of industrial sectors in all countries, in particular developing countries, including, by 2030, encouraging innovation and substantially increasing the number of research and development workers per 1 million people and public and private research and development spending | Indicator: Increased market access and expansion of OSSIS through acquisition by Zimmer Biomet |
| SDG 17: Partnerships for the Goals | Target 17.6: Enhance North-South, South-South, and triangular regional and international cooperation on and access to science, technology, and innovation and enhance knowledge sharing on mutually agreed terms, including through improved coordination among existing mechanisms, particularly at the United Nations level, and through a global technology facilitation mechanism | Indicator: Expansion of the global network for marketing HyProtect™ coating technology |
1. Which SDGs are addressed or connected to the issues highlighted in the article?
- SDG 3: Good Health and Well-being
- SDG 9: Industry, Innovation, and Infrastructure
- SDG 17: Partnerships for the Goals
The article discusses the introduction and marketing of the HyProtect™ coating technology in additional markets for orthopedic revision implants. This relates to improving health and well-being (SDG 3) by reducing the risk of infection in patients at risk. The expansion of OSSIS, the company behind the implants, after its acquisition by Zimmer Biomet highlights the importance of industry, innovation, and infrastructure (SDG 9). Additionally, the partnership between Bio-Gate and OSSIS demonstrates the need for partnerships and cooperation (SDG 17) to enhance access to innovative technologies.
2. What specific targets under those SDGs can be identified based on the article’s content?
- Target 3.8: Achieve universal health coverage, including financial risk protection, access to quality essential healthcare services, and access to safe, effective, quality, and affordable essential medicines and vaccines for all
- Target 9.5: Enhance scientific research, upgrade the technological capabilities of industrial sectors in all countries, in particular developing countries, including, by 2030, encouraging innovation and substantially increasing the number of research and development workers per 1 million people and public and private research and development spending
- Target 17.6: Enhance North-South, South-South, and triangular regional and international cooperation on and access to science, technology, and innovation and enhance knowledge sharing on mutually agreed terms, including through improved coordination among existing mechanisms, particularly at the United Nations level, and through a global technology facilitation mechanism
The targets identified in the article are aligned with the SDGs mentioned above. Target 3.8 focuses on achieving universal health coverage and access to safe and quality healthcare services, which is addressed by the HyProtect™ coating technology in orthopedic revision implants. Target 9.5 emphasizes enhancing scientific research and technological capabilities, which is relevant to the expansion of OSSIS and the adoption of innovative coating technology. Target 17.6 highlights the importance of regional and international cooperation in science, technology, and innovation, which is demonstrated by the partnership between Bio-Gate and OSSIS.
3. Are there any indicators mentioned or implied in the article that can be used to measure progress towards the identified targets?
- Indicator: Increased volume of HyProtect™ coated implants used in orthopedic revisions for patients at risk of infection
- Indicator: Increased market access and expansion of OSSIS through acquisition by Zimmer Biomet
- Indicator: Expansion of the global network for marketing HyProtect™ coating technology
The article mentions indicators that can be used to measure progress towards the identified targets. The increased volume of HyProtect™ coated implants used in orthopedic revisions for patients at risk of infection serves as an indicator for achieving universal health coverage and access to safe healthcare services (Target 3.8). The increased market access and expansion of OSSIS after its acquisition by Zimmer Biomet indicate progress towards enhancing scientific research and technological capabilities (Target 9.5). The expansion of the global network for marketing HyProtect™ coating technology demonstrates efforts in enhancing regional and international cooperation in science, technology, and innovation (Target 17.6).
Behold! This splendid article springs forth from the wellspring of knowledge, shaped by a wondrous proprietary AI technology that delved into a vast ocean of data, illuminating the path towards the Sustainable Development Goals. Remember that all rights are reserved by SDG Investors LLC, empowering us to champion progress together.
Source: medicaldesignandoutsourcing.com
Join us, as fellow seekers of change, on a transformative journey at https://sdgtalks.ai/welcome, where you can become a member and actively contribute to shaping a brighter future.
